Evidence mapPaperPMID 40904329Full record

ArticleJournal of biomedical physics & engineering2025

An Infrared Non-Invasive System for Measuring Blood Glucose: A Primary Study using Serum Samples.

Ramin Jokari, Zahra Mahyari, Mohammad Javad Moulodi, Seyyed Mohammad Fatemi Ghiri, Hadi Tajalizadeh, Ali Loloee Jahromi, Alireza Nakhostin, Gholamreza Abdollahifard, Hossein Parsaei

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ramin JokariStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra MahyariBasamad Azma Novin Pars Co. Ltd, Innovation and Acceleration Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Javad MoulodiBasamad Azma Novin Pars Co. Ltd, Innovation and Acceleration Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyyed Mohammad Fatemi GhiriBasamad Azma Novin Pars Co. Ltd, Innovation and Acceleration Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hadi TajalizadehBasamad Azma Novin Pars Co. Ltd, Innovation and Acceleration Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali Loloee JahromiBasamad Azma Novin Pars Co. Ltd, Innovation and Acceleration Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza NakhostinBasamad Azma Novin Pars Co. Ltd, Innovation and Acceleration Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Gholamreza AbdollahifardDepartment of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein ParsaeiDepartment of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetes is a global concern, with an estimated 2 million individuals expected to be affected by the condition by 2024. Non-invasive glucose monitoring devices can greatly enhance patient care and management. Objective: This study aimed to develop an instrument capable of non-invasively measuring blood glucose levels using an infrared transmitter and receiver, with data processing performed by a dedicated processor. Material and Methods: This analytical study develops a glucometer that incorporates a power supply, a light source, a light detector, a sampler, and signal processing components to enable non-invasive glucose measurements. The instrument was calibrated using sugar solution samples with known glucose concentrations. It was then tested using serum samples from diabetic patients with accuracy, which was evaluated using Clarke's grid analysis. Results: Testing of the designed glucometer revealed that 83% of the serum samples fell within zone A of Clarke's grid analysis, indicating high accuracy. The remaining 17% of samples were classified in zone B, with no samples falling in zones C, D, or E. Conclusion: The developed glucometer demonstrated higher accuracy in measuring glucose concentrations above 200 mg/dl. Despite the use of serum samples in this experiment, 83% of the results were located in zone A leads to the capability of non-invasively measuring blood glucose levels. Further studies are required to validate the device's accuracy in a larger population and assess its utility in clinical practice.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringContinuous Glucose MonitoringDiabetesGlucometerNon-Invasive Blood Glucose Measurement

Identifiers

PMID40904329
PMCPMC12402407

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.